Response to: 'To DAPSA or not to DAPSA? That is not the question' by Schoels et al. by van Mens, L, van de Sande, M, van Kuijk, A, Baeten, D, Coates, L

Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort by van Mens, L, van de Sande, M, van Kuijk, A, Baeten, D, Coates, L

Treat to target in PsA should focus on clinical measures. Response to: ‘DAPSA versus cDAPSA: do we need use CRP?’ by Gonçalves et al. by Van Mens, L, Van De Sande, M, Van Kuijk, A, Baeten, D, Coates, L

Data showing non-conventional HLA-B27 expression in axial joints and gut tissue from B27 transgenic rats, and in frozen and paraffin-fixed synovial SpA tissue by Rysnik, O, McHugh, K, Van Duivenvoorde, L, Van Tok, M, Taurog, J, Kollnberger, S, Baeten, D, Bowness, P

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study by Glatt, S, Taylor, P, McInnes, I, Schett, G, Landewe, R, Baeten, D, Ionescu, L, Strimenopoulou, F, Watling, M, Shaw, S

Non-conventional forms of HLA-B27 are expressed in spondyloarthritis joints and gut tissue by Rysnik, O, McHugh, K, van Duivenvoorde, L, van Tok, M, Guggino, G, Taurog, J, Kollnberger, S, Ciccia, F, Baeten, D, Bowness, P

EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS by Emery, P, Baeten, D, Sieper, J, Braun, J, van der Heijde, D, McInnes, I, Van Laar, J, Landewe, R, Wordsworth, B, Wollenhaupt, J, Kellner, H, Paramarta, I, Bertolino, A, Wright, A, Hueber, W

EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS by Van Laar, J, Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, Landewe, R, Wordsworth, B, Wollenhaupt, J, Kellner, H, Wright, A, Gsteiger, S, Hueber, W

Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Gsteiger, S, Hueber, W

Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions i... by Baeten, D, Bek, S, Wei, J, Brachat, A, Sieper, J, Emery, P, Braun, J, van der Heijde, D, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Paramarta, J, Bertolino, A, Wright, A, Wolfgang, H

LONG TERM INHIBITION OF IL-17A WITH SECUKINUMAB REDUCES SPINAL INFLAMMATION BUT HAS NO INFLUENCE ON FATTY LESIONS AS ASSESSED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOS... by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Hueber, W

Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Hueber, W

Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with... by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Wolfgang, H

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. by Baeten, D, Baraliakos, X, Braun, J, Sieper, J, Emery, P, van der Heijde, D, McInnes, I, van Laar, J, Landewé, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Paramarta, J, Wei, J, Brachat, A, Bek, S, Laurent, D, Li, Y, Wang, Y, Bertolino, A, Gsteiger, S, Wright, A, Hueber, W